Search company, investor...

Predict your next investment

Roche Holding company logo
Holding Company
HEALTHCARE | Pharmaceuticals / Drugs
roche.com

Investments

8

Portfolio Exits

9

Partners & Customers

10

Service Providers

3

About Roche Holding

Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops, and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions which are the pharmaceuticals division and the diagnostics division. The company was founded in 1896 and is based in Basel, Switzerland.

Headquarters Location

Konzern-Hauptsitz Grenzacherstrasse 124

Basel, 4070,

Switzerland

+41-61-688 1111

Want to inform investors similar to Roche Holding about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Roche Holding

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Roche Holding in 7 Expert Collections, including Digital Health.

D

Digital Health

460 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

C

Cancer

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

C

Conference Exhibitors

5,302 items

D

Diabetes

1,903 items

M

Medical Devices

4,400 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

984 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

Latest Roche Holding News

Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products

Feb 2, 2023

02/02/2023 | 01:47am EST Message : By Cecilia Butini Roche Holding AG reported sales growth in 2022, but said it expects a decrease in sales for 2023 due to a drop in the sale of Covid-19 products. The Swiss pharma major posted sales of 63.28 billion Swiss francs ($69.65 billion) for the full year 2022, up from CHF62.80 billion in 2021 and in line with consensus expectations. Net profit declined to CHF13.53 billion from CHF14.94 billion the year prior, missing analysts' expectations of CHF15.09 billion. Core operating profit grew to CHF22.17 billion in the year from CHF21.90 billion the year prior, and core earnings per share also grew to CHF20.30 from CHF19.81 in 2021, the company said. For the year ahead, Roche expects a decrease in sales due to a previously announced CHF5 billion decline in Covid-19 product sales, it said. The expected sales drop is in the low-single digit at constant exchange rates. When excluding the Covid-19 sales decline, the company anticipates "solid underlying sales growth" in both its pharmaceutical and diagnostics division, it said. Write to Cecilia Butini at cecilia.butini@wsj.com (END) Dow Jones Newswires

Roche Holding Investments

8 Investments

Roche Holding has made 8 investments. Their latest investment was in Lead Pharma as part of their Project Finance on November 11, 2020.

CBI Logo

Roche Holding Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/17/2020

Project Finance

Lead Pharma

$11.86M

Yes

1

4/8/2020

Project Finance

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2019

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

10/28/2019

Biz Plan Competition

Subscribe to see more

Subscribe to see more

10

10/2/2018

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/17/2020

4/8/2020

12/19/2019

10/28/2019

10/2/2018

Round

Project Finance

Project Finance

Partnership

Biz Plan Competition

Partnership

Company

Lead Pharma

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$11.86M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Roche Holding Portfolio Exits

9 Portfolio Exits

Roche Holding has 9 portfolio exits. Their latest portfolio exit was Ariosa Diagnostics on August 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/16/2021

Acquired - II

$99M

2

5/18/2021

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

11/13/2020

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

4/1/2019

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

10/15/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/16/2021

5/18/2021

11/13/2020

4/1/2019

10/15/2018

Exit

Acquired - II

Acq - Fin

Divestiture

Spinoff / Spinout

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Roche Holding Acquisitions

57 Acquisitions

Roche Holding acquired 57 companies. Their latest acquisition was Good Therapeutics on September 07, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/7/2022

Series B

$99M

$30.19M

Acquired

14

9/9/2021

$99M

Acquired

1

3/15/2021

$99M

Acq - Pending

26

10/7/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

9/21/2020

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/7/2022

9/9/2021

3/15/2021

10/7/2020

9/21/2020

Investment Stage

Series B

Series B

Grant

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$30.19M

$99M

$99M

Note

Acquired

Acquired

Acq - Pending

Subscribe to see more

Subscribe to see more

Sources

14

1

26

10

10

Roche Holding Partners & Customers

10 Partners and customers

Roche Holding has 10 strategic partners and customers. Roche Holding recently partnered with Sysnav Healthcare on January 1, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

1/25/2023

Partner

Sysnav Healthcare

Sysnav Healthcare announces a multi-year collaboration with Roche based on Sysnav's proprietary movement tracking technology

VERNON , France , Jan. 25 , 2023 / PRNewswire / -- Sysnav and Roche enter a partnership to facilitate development of industry standard outcome measurements in diseases associated with movement impairments , as well as designing the next generation of wearable technology based on Sysnav 's unique technology .

5

1/18/2023

Licensor

Switzerland

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

AC Immune SA has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech , a member of the Roche Group , Eli Lilly and Company , and others , resulting in substantial non-dilutive funding to advance its proprietary programs and > $ 3 billion in potential milestone payments .

2

1/18/2023

Partner

Hong Kong

HKSTP and Roche join hands in strategic collaboration

Through our infrastructure , services , expertise and network of partnerships , Hong Kong Science and Technology Parks Corporation will help establish innovation and technology as a pillar of growth for Hong Kong , while reinforcing Hong Kong 's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse .

1

12/16/2022

Client

China

Subscribe to see more

Subscribe to see more

10

12/15/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

1/25/2023

1/18/2023

1/18/2023

12/16/2022

12/15/2022

Type

Partner

Licensor

Partner

Client

Partner

Business Partner

Sysnav Healthcare

Country

Switzerland

Hong Kong

China

United States

News Snippet

Sysnav Healthcare announces a multi-year collaboration with Roche based on Sysnav's proprietary movement tracking technology

VERNON , France , Jan. 25 , 2023 / PRNewswire / -- Sysnav and Roche enter a partnership to facilitate development of industry standard outcome measurements in diseases associated with movement impairments , as well as designing the next generation of wearable technology based on Sysnav 's unique technology .

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

AC Immune SA has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech , a member of the Roche Group , Eli Lilly and Company , and others , resulting in substantial non-dilutive funding to advance its proprietary programs and > $ 3 billion in potential milestone payments .

HKSTP and Roche join hands in strategic collaboration

Through our infrastructure , services , expertise and network of partnerships , Hong Kong Science and Technology Parks Corporation will help establish innovation and technology as a pillar of growth for Hong Kong , while reinforcing Hong Kong 's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

2

1

10

10

Roche Holding Service Providers

3 Service Providers

Roche Holding has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Pending

Commercial Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Pending

Subscribe to see more

Subscribe to see more

Provider Type

Commercial Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Roche Holding Team

74 Team Members

Roche Holding has 74 team members, including current Chief Executive Officer, President, German De La.

Name

Work History

Title

Status

German De La

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

German De La

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Roche Holding to Competitors

Cepheid Logo
Cepheid

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.

Torus Biosystems Logo
Torus Biosystems

Torus Biosystems develops a syndromic diagnostic device designed for use in testing DNA for scientific and medical research purposes. Its Torus Synestia System provides seamless, comprehensive, sample-to-insight test results for major infectious diseases in a faster format than conventional methods, helping for better patient care and improved outcomes. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Hemex Health Logo
Hemex Health

Hemex creates affordable, life-changing medical diagnostics for under-served people everywhere. Its diagnostic platform is designed to reach populations at risk for malaria and sickle cell disease.

Truvian Sciences Logo
Truvian Sciences

Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.

Genalyte Logo
Genalyte

Genalyte transforms the doctor-patient relationship by providing rapid diagnostic testing right in the doctor's office. The company's technology delivers results to physicians in minutes from just a single drop of blood, yielding better outcomes for the patient, empowering doctors to be more effective, and creating a more efficient healthcare system.

Visby Medical Logo
Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.